Trial · NCT01494584
Results by group824
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 824
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) Following Oral Administration of Ezogabine/Retigabine | Regimen A: Ezogabine/Retigabine (E/R) 300 mg | 1680.0 | 95% Confidence Interval 1162.4 to 2428.2 | Hour*Nanograms/Milliliter (h.ng/mL) | |
| The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450 mg Then 600 mg | 2558.8 | 95% Confidence Interval 1873.4 to 3494.8 | Hour*Nanograms/Milliliter (h.ng/mL) | |
| The Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450/ 600/750 mg Then 900 mg | 3783.8 | 95% Confidence Interval 1059.6 to 13512.0 | Hour*Nanograms/Milliliter (h.ng/mL) | |
| Apparent Clearance (CL/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: Ezogabine/Retigabine (E/R) 300 mg | 178.6 | 95% Confidence Interval 123.5 to 258.1 | Liters/Hour | |
| Apparent Clearance (CL/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450 mg Then 600 mg | 234.5 | 95% Confidence Interval 171.7 to 320.3 | Liters/Hour | |
| Apparent Clearance (CL/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450/ 600/750 mg Then 900 mg | 237.9 | 95% Confidence Interval 66.6 to 849.4 | Liters/Hour | |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: Ezogabine/Retigabine (E/R) 300 mg | Cmax | 370.0 | 95% Confidence Interval 260.9 to 524.7 | Nanograms/Milliliter (ng/mL) |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450 mg Then 600 mg | Cmax | 535.9 | 95% Confidence Interval 344.4 to 833.8 | Nanograms/Milliliter (ng/mL) |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450/ 600/750 mg Then 900 mg | Cmax | 750.9 | 95% Confidence Interval 289.8 to 1945.3 | Nanograms/Milliliter (ng/mL) |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: Ezogabine/Retigabine (E/R) 300 mg | Ctau | 105.32 | 95% Confidence Interval 58.70 to 188.98 | Nanograms/Milliliter (ng/mL) |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450 mg Then 600 mg | Ctau | 199.77 | 95% Confidence Interval 140.67 to 283.72 | Nanograms/Milliliter (ng/mL) |
| Maximum Observed Concentration (Cmax) and Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450/ 600/750 mg Then 900 mg | Ctau | 287.48 | 95% Confidence Interval 44.38 to 1862.12 | Nanograms/Milliliter (ng/mL) |
| Apparent Volume of Distribution (Vd/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: Ezogabine/Retigabine (E/R) 300 mg | 1130.9 | 95% Confidence Interval 511.1 to 2502.1 | Liters | |
| Apparent Volume of Distribution (Vd/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450 mg Then 600 mg | 2118.0 | 95% Confidence Interval 539.4 to 8315.8 | Liters | |
| Apparent Volume of Distribution (Vd/F) Following Oral Administration of Ezogabine/Retigabine | Regimen A: E/R 300/450/ 600/750 mg Then 900 mg | 1934.3 | 95% Confidence Interval NA to NA | Liters | |
| Number of Participants With Any Adverse Event (AE) | Regimen A: Ezogabine/Retigabine 300 mg | 1 | Participants | ||
| Number of Participants With Any Adverse Event (AE) | Regimen A: Ezogabine/Retigabine 300 mg, Then 450 mg | 1 | Participants | ||
| Number of Participants With Any Adverse Event (AE) | Regimen A: Ezogabine/Retigabine 300/450 mg, Then 600 mg | 1 | Participants | ||
| Number of Participants With Any Adverse Event (AE) | Regimen A: Ezogabine/Retigabine 300/450/600 mg, Then 750 mg | 0 | Participants | ||
| Number of Participants With Any Adverse Event (AE) | Regimen A: Ezogabine/Retigabine 300/450/600/750, Then 900 mg | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01494584/results